Technical Data
A2275-75N
Amyloid Beta, 1-42 (CT) (Amyloid A4)
Description:
Alzheimers disease (AD) is characterized by the presence of senile plaques in the brain and blood vessel walls. Amyloid Beta A4 (Ab4) protein has been found to be the principal constituent of senile plaques of ADs patients. The amyloid beta-protein precursor (APP) is proteolytically cleaved to generate the 4kD Ab4 protein. Two variants of Ab4 can be detected; Ab-40 short-tailed and Ab-42 long-tailed.

Applications:
Suitable for use in ELISA, Western Blot, and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
Western Blot: 1:100-1:1000
Immunohistochemistry (FFPE): 1:100-1:2000. Pretreat sections with 70% formic acid for 10-30 minutes. Antibody should be incubated with sections overnight at 4ºC.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG19L34Affinity Purified
SizeStorageShippingSourceHost
200ul-20°CBlue IceHumanMouse
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to the last 6aa of ABx-42 conjugated to KLH through the addition of an N-terminal cysteine.
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4. No stabilizing proteins or preservative added.
Specificity:
Recognizes the C-terminus of human beta amyloid and is specific for the isoform ending at the 42nd amino acid. Species Crossreactivity: mouse
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Helwig M, Hoshino A, Berridge C, Lee SN, Lorenzen N, Otzen DE, Eriksen JL, and Lindberg I. The Neuroendocrine Protein 7B2 Suppresses the Aggregation of Neurodegenerative Disease-related Proteins. J. Biol. Chem.; 288: 1114 - 1124, 2013. 2. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, and Ihara Y. y-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of -Carboxyl Terminal Fragment. J. Neurosci.; 29: 13042 - 13052, 2009. 3. Parvathy, S., et al., (2001), “Correlation between ABx-40-, ABx-42-, and ABx-43- containing amyloid plaques and cognitive decline”, Arch. Neurol., 58, 2025–2032.